• PDF / 169,422 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 56 Downloads / 158 Views

DOWNLOAD

REPORT

---

1 S

Hepatotoxicity and neutropenia: 3 case reports In a single–centre retrospective study involving 32 consecutive postmenopausal patients with metastatic breast cancer treated with ribocicib or palbociclib in combination with endocrine therapy (ET) as the first line treatment, 3 womens [exact ages not stated] were described, of whom one woman developed repeating neutropenia during treatment with palbociclib and one woman developed repeating neutropenia during treatment with ribociclib. One woman developed grade III hepatotoxicity during treatment with ribociclib for metastatic breast cancer [routes, dosages, durations of treatments to reactions onsets and outcomes not stated]. The postmenopausal women, who had metastatic breast cancer, received treatment with ribocicib or palbociclib. Out of the 3 women, 1 woman, who received treatment with palbociclib, required dose reduction due to repeating neutropenia. The remaining two women received treatment with ribocicib; of these two women, 1 woman required dose reduction in ribocicib due to repeating neutropenia and the other woman discontinued ribocicib therapy due to grade III hepatotoxicity. Majic A, et al. Hematologic toxicity of cyclin dependent kinase 4/6 (CDK4/6) inhibitors palbociclib and ribociclib during first three cycles of 1st line treatment of metastatic breast cancer-retrospective analysis in single centre. Libri Oncologici 48 (Suppl. 1): 99 (plus poster) abstr. P17, Jan 2020. Available from: URL: https://hrcak.srce.hr/243032 803520403 [abstract]

0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Dec 2020 No. 1834